FDA advisers vote unanimously to back the first mRNA flu vaccine: how the process unfolded
The independent vaccine panel of the US Food and Drug Administration (VRBPAC) took up Moderna's mRNA-based flu vaccine this week. According to The Guardian, after hours of technical presentation and debate the panel voted unanimously in favour. The decision is subject to final approval by FDA leadership, but the panel is historically a strong reference point.
The candidate vaccine is being developed under the code mRNA-1010. As with COVID-19 vaccines, it carries genetic instructions for a flu antigen recognised on the cell surface. Its biggest difference from classic egg-based vaccines is that the manufacturing cycle for one season can be cut roughly in half, to between two and three months.
The critical data came from a phase 3 study with 24,000 participants. The findings: the vaccine reduced laboratory-confirmed flu cases by about 56% and severe-flu hospitalisations by 79%. The comparator arm was a conventional seasonal quadrivalent flu vaccine.
The safety profile aligns with the known mRNA-vaccine pattern: injection-site pain, mild fever and fatigue. The serious-adverse-event rate (notably myocarditis) stayed below the rare figures observed with COVID-19 vaccines. Panel members recommended extending the myocarditis monitoring plan to a five-year post-approval follow-up.
The process this year was unusually contested. A drawn-out FDA internal review created a public perception of "political" friction. The panel session included an agenda item — separate from the vaccine dossier itself — on misinformation targeting the vaccine on social media.
FDA Commissioner Robert Califf said after the panel that the "vote is a clear scientific signal." One independent panel member, speaking to the New York Times afterwards, said: "The decision could have been controversial, but the data alone weighs heavily."
Clinically, the most immediate impact is on the manufacturing calendar. Modern flu vaccines are refreshed early in the season to match dominant strains; halving the manufacturing cycle means updated antigen formulations matching panel forecasts from August-September can be ready in early September instead of late October.
Public-health experts highlighted a second key point: the cost per vial may fall below that of traditional egg-based manufacturing. That is a decisive parameter for extending global flu-vaccine access beyond Europe and the US. According to WHO supply teams, the coverage rate of existing egg-based vaccines in low-income countries hovers around 25%.
Precision debates over target populations continue. One important clinical question is the relative performance of the mRNA vaccine compared with high-dose or adjuvanted versions used for adults aged 65 and over. Sub-group analyses in the phase 3 study showed the effect was somewhat lower in older adults but remained significant.
The general message: the FDA's final decision, expected within 30 days, points toward conditional approval. If approval comes through, mRNA-1010 could be distributed as an option for next year's flu season. In pharmaceutical literature this will be assessed as the first major clinical win for the mRNA platform outside COVID-19.
Read next
Do humans have hidden regenerative powers? What the new research says
Science Daily covers new research showing that humans carry the same regeneration genes that drive limb regrowth in salamanders and axolotls — but kept silent in normal conditions. The finding could reshape the trajectory of regenerative medicine.
Think you're eating healthy? You may be missing this heart-protecting nutrient
A new Tufts University study reports that a large share of adults who consider their diet healthy fall short on omega-3 intake — the nutrient most strongly linked to heart protection. The researchers say fish, leafy greens and walnuts close the gap.
Kidney cancer rates near Pfas factory in Lancashire flagged as 'major source of concern'
A study reported by the Guardian shows that kidney cancer rates around a Pfas-producing factory in Lancashire have run above the UK average for two decades. The findings reignite the debate over how Britain regulates 'forever chemicals'.
Cambrian's experimental longevity drug mimics exercise: what the first human data show
In an early human study run by Cambrian Bio, an experimental molecule activated mitochondrial genes and produced blood-marker changes that mimic the effects of exercise. STAT News explains what the data show — and the questions that remain.
Do wearables actually help people with cardiovascular disease? What the latest evidence says
Smart watches and rings now routinely track steps, heart rhythm and sleep. STAT News reviews recent meta-analyses showing where wearables produce measurable clinical benefit for people with cardiovascular disease — and where the evidence still falls short.
